Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study.

Chalmers JD, Shteinberg M, Mall MA, O'Donnell AE, Watz H, Gupta A, Frahm E, Eleftheraki A, Rauch J, Chotirmall SH, Armstrong AW, Eickholz P, Hasegawa N, Sauter W, McShane PJ

Open source

DOI
10.1183/13993003.01551-2024
Published
2025 Jan
Container
The European respiratory journal
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1183/13993003.01551-2024,
  title = {Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study.},
  author = {Chalmers JD and Shteinberg M and Mall MA and O'Donnell AE and Watz H and Gupta A and Frahm E and Eleftheraki A and Rauch J and Chotirmall SH and Armstrong AW and Eickholz P and Hasegawa N and Sauter W and McShane PJ},
  year = {2025},
  journal = {The European respiratory journal},
  doi = {10.1183/13993003.01551-2024},
  url = {https://doi.org/10.1183/13993003.01551-2024}
}

RIS

TY  - JOUR
TI  - Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study.
AU  - Chalmers JD
AU  - Shteinberg M
AU  - Mall MA
AU  - O'Donnell AE
AU  - Watz H
AU  - Gupta A
AU  - Frahm E
AU  - Eleftheraki A
AU  - Rauch J
AU  - Chotirmall SH
AU  - Armstrong AW
AU  - Eickholz P
AU  - Hasegawa N
AU  - Sauter W
AU  - McShane PJ
PY  - 2025
JO  - The European respiratory journal
DO  - 10.1183/13993003.01551-2024
UR  - https://doi.org/10.1183/13993003.01551-2024
ER  - 

APA

JD, C., M, S., MA, M., AE, O., H, W., A, G., E, F., A, E., J, R., SH, C., AW, A., P, E., N, H., W, S., & PJ, M. (2025). Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study.. The European respiratory journal. https://doi.org/10.1183/13993003.01551-2024

Source records